Lumos Diagnostics Holdings Ltd
Company Profile
Business description
Lumos Diagnostics Holdings Ltd is engaged in selling Products and providing Services to customers. Its product offering includes rapid, point-of-care diagnostic test products, mainly focused on the diagnosis and management of infectious diseases. Its product is FebriDx, a point-of-care test for detecting and differentiating viral and bacterial respiratory infections. Its Service offering includes contract research and development services specialising in innovation, development, manufacturing and commercialisation of point-of-care diagnostic test solutions. The Company has one operating segment, being the provision of point-of-care diagnostics goods and services. It operates in the United States and Australia, with the majority of revenue generated from the United States.
Contact
2724 Loker Avenue West
CarlsbadCA92010
USAT: +1 855 586-6739
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,859.20 | 4.50 | 0.05% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,272.11 | 95.15 | 0.19% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,040.34 | 68.05 | 0.28% |
| NASDAQ | 27,425.37 | 234.51 | 0.86% |
| Nikkei 225 | 69,946.86 | 1,637.40 | 2.40% |
| NZX 50 Index | 13,699.02 | 18.53 | 0.14% |
| S&P 500 | 7,772.03 | 49.31 | 0.64% |
| S&P/ASX 200 | 8,686.40 | 4.30 | 0.05% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |